Position in EOLS
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$581,306
+$571,750 QoQ
Shares Held
141,437
+9742.5% QoQ
Ownership
0.215%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
9 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in EOLS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026NATIXIS holds $42,325,153 across 10 Drug Manufacturers - Specialty & Generic names. EOLS ranks #6 (1.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
281,576 | $33,285,098 | |
| 2 | SUPN |
Supernus Pharmaceuticals, Inc.
|
85,200 | $4,403,988 | |
| 3 | VTRS |
Viatris Inc
|
134,531 | $1,817,513 | |
| 4 | PCRX |
Pacira BioSciences, Inc.
|
34,000 | $768,400 | |
| 5 | UTHR |
UNITED THERAPEUTICS Corp
|
1,175 | $696,751 | |
| 6 | EOLS |
Evolus, Inc.
This page
|
141,437 | $581,306 | |
| 7 | TEVA |
Teva Pharmaceutical Industries Ltd
|
13,589 | $409,300 | |
| 8 | NBIX |
Neurocrine Biosciences Inc
|
2,647 | $348,715 |
All Filings in EOLS
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $581,306 | 141,437 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $9,556 | 1,437 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $18,573 | 3,025 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $29,950 | 3,252 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $54,122 | 4,499 | Shares | Sole | 2025-07-18 | |
| 2024-12-31 | $49,668 | 4,499 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $85,746 | 5,293 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $68,083 | 6,275 | Shares | Sole | 2024-08-13 | |
| 2024-03-31 | $489,244 | 34,946 | Shares | Sole | 2024-05-13 | |
| No filing history on record for this holder in this stock. | ||||||